NIH team touts experimental Epstein-Barr virus vaccine; Madison Vaccines pairs its prostate cancer jab with Keytruda;

> A nanoparticle-based experimental vaccine, developed by a team from the National Institute of Allergy and Infectious Diseases and its collaborators, was shown to induce antibodies against Epstein-Barr virus in mice and primates. Release

> Madison Vaccines initiated a combination trial of its lead prostate cancer vaccine candidate paired with Merck's ($MRK) checkpoint inhibitor Keytruda. Release

> Emergent BioSolutions ($EBS) received a $44 million contract option for the supply of its Vigiv--which treats complications due to smallpox vaccination--to the national stockpile. Release

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.